What Nader actually said is that CytoDyn had been approached by some countries including Indonesia that they could get Leronlimab marketed without having a prior EUA authorization. He said that in Turkey and Brazil no EUA was necessary also. He had not yet decided to pursue those options. You may parse that anyway you would like.